Vioxx users who claim the drug increased their risk of heart ailments may pursue their class action suit against Merck & Co. Inc. for funding of a medical monitoring program.

A New Jersey appeals court, while expressing no opinion on the viability of the product liability claims, ruled that the trial judge had dismissed them too hastily, simply because the plaintiffs had not demonstrated harm.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]